A Potential New Option for Targeted Treatment of Pancreatic Cancer is on the Horizon
TIGeR-PaC is Enrolling Patients Across the Country
The TIGeR-PaC clinical trial is currently enrolling newly-diagnosed locally advanced pancreatic cancer patients. TIGeR-PaC is a randomized study of Trans-Arterial Micro-Perfusion™ (TAMP™) versus systemic chemotherapy. The goal of the trial is to prove extended median survival and improved quality of life through targeted delivery of therapy.
Are you a candidate?
Candidate patients must meet the following criteria:
- Histologically-confirmed pancreatic cancer with initial diagnosis within 6 weeks of consent
- Not a candidate for surgery
- No prior therapy for pancreatic cancer
If you meet the criteria or have questions about the TIGeR-PaC trial, contact RenovoRx.
For more information visit bit.ly/TIGeR-PaC.